| Parameter | Value | |
| Gender | Male | 54 (54.0%) |
| Female | 46 (46.0%) | |
| Mean age | 53.94 ± 14.3 | |
| Hepatomegaly (positive N/100) | 17 (17.0%) | |
| Splenomegaly (positive N/100) | 43 (43.0%) | |
| Lymphadenopathy (positive N/100) | 12 (12.0%) | |
| CD56 (positive N/100) | 56 (56.0%) | |
| CD16 (positive N/100) | 54 (54.0%) | |
| FAB classification | AML M1-M2 | 42 (42.0%) |
| AML M3 | 17 (17.0%) | |
| AML M4-M5 | 41 (41.0%) | |
| Cytogenetic | t (8; 21) (positive N/24) | 4 (16.7%) |
| Inver 16 (positive N/22) | 8 (36.4%) | |
| 11q23 rearrangement (positive N/8) | 4 (50.0%) | |
| t (15; 17) (positive N/14) | 13 (92.9%) | |
| Response to TTT | Remission (N/100) | 78 (78.0%) |
| Relapse (N/100) | 22 (22.0%) | |
| Survival | Lived (N/100) | 56 (56.0%) |
| Dead (N/100) | 44 (44.0%) | |
| FLT3 NPM | Positive 38/100 Positive 56/100 | 38% 56% |
| Groups | AML group (with CD155 < 5.35) | 50 (50.0%) |
| AML group (with CD155 > 5.35) | 50 (50.0%) | |